Sugi Predict

Sugi Predict / Compounds / SCHEMBL16660929

SCHEMBL16660929

SCHEMBL16660929

CCOC(=N)c1ccc(Cl)nc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 2/20 1.00
▸ RAB9A P51151 4/20 0.55
▸ L3MBTL1 Q9Y468 4/20 0.49
▸ MAPT P10636 3/20 0.49
▸ PKM P14618 2/20 0.49
▸ POLB P06746 1/20 0.49
▸ NAPRT Q6XQN6 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.46
▸ LMNA P02545 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ GAA P10253 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ CHRNB2 P17787 1/20 0.40
▸ CHRNA7 P36544 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2277833 0.81 DGAT1 (0.69) DGAT1RAB9AL3MBTL1MAPTPKM
SCHEMBL20414659 0.81 DGAT1 (0.69) DGAT1RAB9AL3MBTL1MAPTPOLB
SCHEMBL71884 0.81 DGAT1 (0.68) DGAT1RAB9AL3MBTL1MAPTPKM
SCHEMBL29723823 0.81 DGAT1 (0.68) DGAT1RAB9AL3MBTL1MAPTPKM
SCHEMBL13108706 0.78 DGAT1 (0.62) DGAT1LMNAKMT2AMEN1ALDH1A1
SCHEMBL1220000 0.77 DGAT1 (0.62) DGAT1MAPTPOLBLMNAKMT2A
Hydrochloric Acid SCHEMBL20766398 0.76 DGAT1 (0.60) DGAT1LMNAKMT2AMEN1ALDH1A1
Hydrochloric Acid SCHEMBL17512889 0.76 DGAT1 (0.60) DGAT1LMNAKMT2AMEN1ALDH1A1
SCHEMBL8662091 0.76 DGAT1 (0.60) DGAT1RAB9AL3MBTL1MAPTPKM
SCHEMBL3173315 0.76 DGAT1 (0.60) DGAT1RAB9AL3MBTL1MAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107849053-B Spiro compounds 里科瑞尔姆IP控股有限责任公司 2020-10-30 — — CN disclosed
US-20200268714-A1 SPIROCYCLIC COMPOUNDS KALYRA PHARMACEUTICALS, INC. 2020-08-27 — — US disclosed
US-20200268714-A1 SPIROCYCLIC COMPOUNDS KALYRA PHARMACEUTICALS, INC. 2020-08-27 — — US disclosed
EP-3277690-B1 SPIROCYCLIC COMPOUNDS RECURIUM IP HOLDINGS LLC (US) 2020-02-26 — — EP disclosed
EP-3277690-B1 SPIROCYCLIC COMPOUNDS RECURIUM IP HOLDINGS LLC (US) 2020-02-26 — — EP disclosed
US-20190201380-A1 SPIROCYCLIC COMPOUNDS KALYRA PHARMACEUTICALS, INC. 2019-07-04 — — US disclosed
US-20190201380-A1 SPIROCYCLIC COMPOUNDS KALYRA PHARMACEUTICALS, INC. 2019-07-04 — — US disclosed
US-10308636-B2 Aromatic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-06-04 — — US disclosed
EP-2862856-B1 IMIDAZOLE AND TRIAZOLE COMPOUNDS AS DGAT-1 INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2018-08-01 — — EP disclosed
US-20180207132-A1 SPIROCYCLIC COMPOUNDS RECURIUM IP HOLDINGS, LLC 2018-07-26 — — US disclosed
EP-3277690-A1 SPIROCYCLIC COMPOUNDS Kalyra Pharmaceuticals, Inc. (US) 2018-02-07 — — EP disclosed
US-20170050950-A1 AROMATIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-02-23 — — US disclosed
US-20170050950-A1 AROMATIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-02-23 — — US disclosed
US-9546155-B2 Aromatic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-01-17 — — US disclosed
US-9546155-B2 Aromatic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-01-17 — — US disclosed
WO-2016161160-A1 SPIROCYCLIC COMPOUNDS KALYRA PHARMACEUTICALS, INC. (US) 2016-10-06 — — WO disclosed
WO-2016161160-A1 SPIROCYCLIC COMPOUNDS KALYRA PHARMACEUTICALS, INC. (US) 2016-10-06 — — WO disclosed
US-20150158844-A1 AROMATIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-06-11 — — US disclosed
US-20150158844-A1 AROMATIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-06-11 — — US disclosed
EP-2862856-A1 AROMATIC HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2015-04-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150158844-A1 AROMATIC HETEROCYCLIC COMPOUND GPR119, NR0B1, BET1 DGAT1 1688/4885RAB9A 3324/4885L3MBTL1 894/4885
US-20200268714-A1 SPIROCYCLIC COMPOUNDS PKD1, AR, PKD2 DGAT1 1617/4885RAB9A 1456/4885L3MBTL1 4544/4885
US-10308636-B2 Aromatic heterocyclic compound GPR119, NR0B1, BET1 DGAT1 1688/4885RAB9A 3324/4885L3MBTL1 894/4885
US-20190201380-A1 SPIROCYCLIC COMPOUNDS PKD1, AR, PKD2 DGAT1 1617/4885RAB9A 1456/4885L3MBTL1 4544/4885
US-20180207132-A1 SPIROCYCLIC COMPOUNDS PKD1, AR, PKD2 DGAT1 1617/4885RAB9A 1456/4885L3MBTL1 4544/4885
US-20170050950-A1 AROMATIC HETEROCYCLIC COMPOUND GPR119, NR0B1, BET1 DGAT1 1688/4885RAB9A 3324/4885L3MBTL1 894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback